Kevin L. Stephans
Cleveland Clinic(US)
Publications by Year
Research Areas
Advanced Radiotherapy Techniques, Lung Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Prostate Cancer Treatment and Research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy(2016)378 cited
- → Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer(2018)285 cited
- → Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial(2022)228 cited
- → Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable Patients(2009)153 cited
- → Prediction of Chest Wall Toxicity From Lung Stereotactic Body Radiotherapy (SBRT)(2011)139 cited
- → A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic Experience(2009)134 cited
- → Intensity-Modulated Radiotherapy–Based Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Lung Cancer: Excellent Local Control(2009)128 cited
- → Differential Distribution and Function of Hyperpolarization-Activated Channels in Sensory Neurons and Mechanosensitive Fibers(2004)120 cited
- → Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial(2017)119 cited
- → One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial(2019)106 cited